TITLE

Is Inhaled Nitric Oxide Therapy in Neonates With Primary Pulmonary Hypertension in Developing Countries Like India Feasible?

AUTHOR(S)
Joshi, Rajan; Patil, Sheela S.; Dominic, Sili; Pratap, Usha; Rajhans, Arti P.; Devaskar, Uday P.
PUB. DATE
May 2007
SOURCE
Perinatology: Journal of Perinatal & Neonatal Care;May/Jun2007, Vol. 9 Issue 3, p108
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Primary pulmonary hypertension (PPHN) continues to be a major cause of hypoxic respiratory failure (HRF) among term and near term neonates world wide. In developed countries neonatal mortality and morbidity from PPHN and the need for extra-corporeal membrane oxygenator (ECMO) has decresed largely due to the use of inhalational Nitric Oxide (iNO). However, iNO therapy is generally not available in developing countries like India. A significant improvement in the care of the critically ill newborns has occurred in India during the last decade. However, for most neonates the cost of health care is still not paid by the government or the third party payer. As a result the family has to bear the brunt. Therefore introduction of newer medical technologies like iNO has to be cost effective. In addition, introduction of newer technologies is generally met with several obstacles, both technical and logistic in nature. Here we describe our experience with the introduction of iNO. Eighteen babies with mean B.W. 3.1 kg and G.A. 38.9 weeks were treated with iNO. The iNO delivery system was assembled. Nitric oxide (99.9% pure) supplied by a local company was used. The cost of initial investment, excluding nurse and physician education and training, was ∼ IRS 200,000. Neonates with HRF with PPHN were treated with iNO at the discretion of a neonatologist. All neonates were treated with 100% FiO2, mechanical ventilation (mean air way pressure >18, n = 15 with high frequency ventilator, and n = 3 conventional) and cardiotonic drugs prior to initiating iNO. In all babies echocardiogram was obtained to rule out the presence of a cardiac anomaly. NO and Nitrogen Dioxide (NO2) concentration were monitored. After initial investment, education and training, treatment with iNO was possible. Out of 18 babies treated with iNO, 2 babies, both transported from another hospital in a critical condition, died within an hour of initiation of iNO therapy. Three babies did not show any improvement in the oxygenation following initial 2 hours of iNO therapy. Therefore iNO was discontinued and all 3 of them died. Of the remaining 13 babies who had shown a significant improvement in oxygenation after initial 2 hours of iNO therapy, 6 (46 %) survied and 7 died (54 %). Average cost of treatment during iNO therapy was ∼ IRS 7000 / day. Most but not all parents were able to pay the cost of iNO. We conclude that even in a developing country like India, iNO therapy can be introduced. Not only it can be life saving but it can be cost effective.
ACCESSION #
27694400

 

Related Articles

  • Feasibility of Nitric Oxide Administration by Oxygen Hood in Neonatal Pulmonary Hypertension. Ambalavanan, Namasivayam; St. John, Elaine; Carlo, Waldemar A; Bulger, Arlene; Philips, Joseph B // Journal of Perinatology;Jan2002, Vol. 22 Issue 1, p50 

    OBJECTIVE: To test the hemodynamic efficacy and feasibility of nitric oxide (NO) administration by oxygen hood in neonatal pulmonary hypertension. STUDY DESIGN: A double-hood apparatus was used in which a combination of NO, O[SUB2], and N[SUB2] was introduced into the inner hood and suctioned...

  • Disease-related response to inhaled nitric oxide in newborns with severe hypoxaemic respiratory failure. French Paediatric Study Group of Inhaled NO. Mercier, J.-C.; Lacaze, T.; Storme, L.; Rozé, J.-C.; Dinh-Xuan, A. Tuan; Dehan, M.; Rozé, J C; Dinh-Xuan, A T // European Journal of Pediatrics;1998, Vol. 157 Issue 9, p747 

    Inhaled nitric oxide (iNO) has been shown to improve oxygenation in severe persistent pulmonary hypertension of the newborn (PPHN). However, PPHN is often associated with various lung diseases. Thus, response to iNO may depend upon the aetiology of neonatal acute respiratory failure. A total of...

  • Inhaled Nitric Oxide in the Treatment of Moderate Persistent Pulmonary Hypertension of the Newborn: A Randomized Controlled, Multicenter Trial. Sadiq, H Farouk; Mantych, Gregory; Benawra, Raghbir S; Devaskar, Uday P; Hocker, James R // Journal of Perinatology;Mar2003, Vol. 23 Issue 2, p98 

    OBJECTIVE:: Inhaled nitric oxide (iNO) improves oxygenation and reduces the need for extracorporeal membrane oxygenation in infants with severe persistent pulmonary hypertension of the newborn (PPHN). The effectiveness of iNO in the treatment of moderate PPHN has not been adequately defined. We...

  • Sildenafil: Emerging Pulmonary Vascodilator for Pulmonary Hypertension due to Congenial Heart Disease. Raja, Shahzad G. // Internet Journal of Pediatrics & Neonatology;2005, Vol. 5 Issue 1, p39 

    Pulmonary arterial hypertension is a life-threatening condition for which therapeutic options are limited. The current expensive gold standard-inhaled nitric oxide-is usually not affordable in developing countries. Moreover, nitric oxide has also not proved to be the single magic bullet for...

  • The management of neonatal pulmonary hypertension. Dhillon, Rami // Archives of Disease in Childhood -- Fetal & Neonatal Edition;May2012, Vol. 97 Issue 3, pF223 

    Most neonates with clinically signifi cant pulmonary hypertension (PH) will have either persistent PH of the newborn (PPHN) or bronchopulmonary dysplasia. Cyanotic congenital heart disease must be actively ruled out as part of the differential diagnosis of PPHN. The maintenance of ductal patency...

  • Nitric oxide. Young, Duncan // Continuing Education in Anaesthesia, Critical Care & Pain;Dec2002, Vol. 2 Issue 6, p161 

    This article discusses the use of nitric oxide in the treatment of diseases. It explains the ability of inhaled nitric oxide to reduce the use of extra-corporeal membrane oxygenation (ECMO) in neonates with pulmonary hypertension. It also notes the effectiveness of inhaled nitric oxide in...

  • Nitric Oxide Administration Using an Oxygen Hood: A Pilot Trial. Ambalavanan, Namasivayam; El-Ferzli, George T.; Roane, Claire; Johnson, Robert; Carlo, Waldemar A. // PLoS Clinical Trials;Feb2009, Vol. 6 Issue 2, Special section p1 

    Background: We have shown earlier that inhaled nitric oxide (iNO) administered by oxygen hood reduces pulmonary hypertension in an animal model (J Perinatol 2002; 22:50-6). Our objective in this study was to determine feasibility of iNO by oxygen hood in neonates with elevated alveolar-arterial...

  • Neonatal pulmonary hypertension treated with inhaled nitric oxide and high-frequency ventilation. Coates, E. W.; Klinepeter, M. E.; O'Shea, T. M. // Journal of Perinatology;Oct2008, Vol. 28 Issue 10, p675 

    Term and near-term infants with pulmonary hypertension are frequently treated with inhaled nitric oxide. This therapy can be delivered with high-frequency ventilation, but there has been limited study of the relative effectiveness of high-frequency jet ventilation and high-frequency oscillatory...

  • How has research in the past 5 years changed my clinical practice. Greenough, Anne // Archives of Disease in Childhood -- Fetal & Neonatal Edition;Sep2007, Vol. 92 Issue 5, pF404 

    This article discusses how research in the past 5 years into management strategies influencing respiratory outcomes has changed (or not changed) the author's clinical practice. Changes include using inhaled nitric oxide but no longer systemic pulmonary vasodilators in term born infants with...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics